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Abstract: OBJECTIVES The effects of vitamin C administration on clinical outcome in critically ill
patients remain controversial. DATA SOURCES Online databases were searched up to October 1, 2018.
STUDY SELECTION We included randomized controlled trials on the use of vitamin C (any regimen)
in adult critically ill patients versus placebo or no therapy. DATA EXTRACTION Risk ratio for dichoto-
mous outcome and standardized mean difference for continuous outcome with 95% CI were calculated
using random-effects model meta-analysis. DATA SYNTHESIS Forty-four randomized studies, 16 per-
formed in ICU setting (2,857 patients) and 28 in cardiac surgery (3,598 patients), published between 1995
and 2018, were included in the analysis. In ICU patients, vitamin C administration was not associated
with a difference in mortality (risk ratio, 0.90; 95% CI, 0.74-1.10; p = 0.31), acute kidney injury, ICU
or hospital length of stay compared with control. In cardiac surgery, vitamin C was associated to a
reduction in postoperative atrial fibrillation (risk ratio, 0.64; 95% CI, 0.52-0.78; p < 0.0001), ICU stay
(standardized mean difference, -0.28 d; 95% CI, -0.43 to -0.13 d; p = 0.0003), and hospital stay (stan-
dardized mean difference, -0.30 d; 95% CI, -0.49 to -0.10 d; p = 0.002). Furthermore, no differences in
postoperative mortality, acute kidney injury, stroke, and ventricular arrhythmia were found. CONCLU-
SIONS In a mixed population of ICU patients, vitamin C administration is associated with no significant
effect on survival, length of ICU or hospital stay. In cardiac surgery, beneficial effects on postoperative
atrial fibrillation, ICU or hospital length of stay remain unclear. However, the quality and quantity of
evidence is still insufficient to draw firm conclusions, not supporting neither discouraging the systematic
administration of vitamin C in these populations. Vitamin C remains an attractive intervention for future
investigations aimed to improve clinical outcome.
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Objectives: The effects of vitamin C administration on clinical out-
come in critically ill patients remain controversial.
Data Sources: Online databases were searched up to October 
1, 2018.
Study Selection: We included randomized controlled trials on the 
use of vitamin C (any regimen) in adult critically ill patients versus 
placebo or no therapy.
Data Extraction: Risk ratio for dichotomous outcome and stan-
dardized mean difference for continuous outcome with 95% CI 
were calculated using random-effects model meta-analysis.
Data Synthesis: Forty-four randomized studies, 16 performed in 
ICU setting (2,857 patients) and 28 in cardiac surgery (3,598 
patients), published between 1995 and 2018, were included in 
the analysis. In ICU patients, vitamin C administration was not as-
sociated with a difference in mortality (risk ratio, 0.90; 95% CI, 
0.74–1.10; p = 0.31), acute kidney injury, ICU or hospital length 
of stay compared with control. In cardiac surgery, vitamin C was 
associated to a reduction in postoperative atrial fibrillation (risk 
ratio, 0.64; 95% CI, 0.52–0.78; p < 0.0001), ICU stay (stan-
dardized mean difference, –0.28 d; 95% CI, –0.43 to –0.13 d; 
p = 0.0003), and hospital stay (standardized mean difference, 
–0.30 d; 95% CI, –0.49 to –0.10 d; p = 0.002). Furthermore, no 
differences in postoperative mortality, acute kidney injury, stroke, 
and ventricular arrhythmia were found.
Conclusions: In a mixed population of ICU patients, vitamin C ad-
ministration is associated with no significant effect on survival, 
length of ICU or hospital stay. In cardiac surgery, beneficial effects 
on postoperative atrial fibrillation, ICU or hospital length of stay 
remain unclear. However, the quality and quantity of evidence is 
still insufficient to draw firm conclusions, not supporting neither 
discouraging the systematic administration of vitamin C in these 
populations. Vitamin C remains an attractive intervention for future 
investigations aimed to improve clinical outcome. (Crit Care Med 
2019; XX:00–00)
Key Words: ascorbic acid; cardiac surgery; critical care; intensive 
care; perioperative medicine; vitamin C
M
ost critically ill patients, such as those with septic shock 
or undergoing cardiac surgery, suffer from pathophys-
iologic conditions that lead toward a systemic inflam-
matory response that can increase oxidative stress. In this scenario, 
there is a drastic reduction in plasma levels of various micronutri-
ents and trace elements with antioxidant properties, whereas the 
circulating oxidative molecules rise, resulting in an overwhelming 
increase of their levels that can lead to organ failure and death (1–
4). Therefore antioxidant defenses repletion could theoretically 
results in a beneficial therapeutic effect in the critically ill patient 
(4). However, randomized evidence on antioxidant is highly in-
consistent, with no clear benefit yet established.
Vitamin C, also known as ascorbic acid or ascorbate, is an 
antioxidant molecule with pleiotropic properties that may 
contribute to reduce oxidative stress and organ dysfunction, 
together with a positive impact on tissue perfusion (2). It has 
been suggested that vitamin C may be helpful as adjunctive 
therapy in septic shock (5) and it may also play a role in car-
diac surgery, particularly in prevention of postoperative atrial 
fibrillation (6). Furthermore, IV vitamin C administration 
could be an effective way to restore the physiologic levels of DOI: 10.1097/CCM.0000000000003700
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this micronutrient, and supra-physiologic doses of vitamin C 
could have further beneficial effects (7–9). Side effects are rare, 
but reported in the literature (1, 4, 10). Nevertheless, despite 
there is a rationale in favor of the use of vitamin C, the clin-
ical effectiveness of vitamin C supplementation is still unclear. 
In this systematic review with meta-analysis, meta-regression, 
and trial sequential analysis (TSA), we aimed to assess the 
effect of vitamin C administration on major clinical outcome 
in ICU or cardiac surgery patients.
MATERIALS AND METHODS
The present systematic review was conducted in compliance 
with Cochrane methodology (11), Preferred Reporting Items 
Systematic Reviews and Meta-Analysis (PRISMA) guidelines 
(12), and according to a pre-published protocol on the interna-
tional prospective register of systematic reviews (PROSPERO, 
CRD42017069790). A complete PRISMA checklist is provided 
in eTable 1 (Supplemental Digital Content 1, http://links.lww.
com/CCM/E416) (13).
Search Strategy
Two investigators (A.P.,V.F.G.) independently searched 
PubMed, EMBASE, and the Cochrane Central Register of 
clinical trials (last updated October 1, 2018) for appropriate 
articles. The full PubMed search strategy is available in the 
supplement (eMethods 1, Supplemental Digital Content 1, 
http://links.lww.com/CCM/E416) and it includes all the most 
common vitamin C definitions employed in the literature. 
Abstracts from recent international conferences were searched 
for additional relevant studies. In addition, we hand scanned 
references of retrieved articles and pertinent reviews of the lit-
erature. No language restriction was enforced.
Study Selection
References obtained from searches were first independently 
examined at an abstract level by two investigators (A.P., V.F.G) 
and then, if potentially relevant, collected as complete articles. 
Eligible studies met the following PICOS criteria: 1) Popula-
tion: adult ICU or cardiac surgery patients; 2) Intervention: any 
type of vitamin C formulation and regimen; 3) Comparison 
intervention: placebo or no therapy; 4) Outcome: mortality at 
longest follow-up available; and 5) Study design: randomized 
controlled trials (RCTs). There were no restrictions on vitamin 
C formulation and dose or time of administration. The exclu-
sion criteria were overlapping populations and pediatric stud-
ies. Two investigators (A.P., A.M.D.) independently assessed 
selected studies for the final analysis, with eventual divergences 
finally resolved by consensus. If the article did not report data 
on primary or secondary outcomes, the corresponding author 
was contacted for further information.
Data Abstraction and Study Characteristics
Three authors (A.P., A.M.D., V.F.G.) extracted relevant informa-
tion from each selected study and entered them into predefined 
databases; divergences were resolved by consensus with a fourth 
author (G.L.). We collected potential sources of significant clin-
ical heterogeneity, such as study design, sample size, clinical 
setting, inclusion and exclusion criteria, vitamin C regimen 
and association with other drugs, control treatment, as well as 
primary and secondary endpoints. We evaluated the possible 
authors’ conflicts of interests and the funding of each study.
The primary endpoint of the present review was mortality at 
the longest follow-up available. Secondary outcomes included 
acute kidney injury (AKI), supraventricular arrhythmia, ven-
tricular arrhythmia, stroke, length of ICU stay, and length of 
hospital stay. The outcomes were reported as per-trial definition. 
We applied the intention-to-treat methods whenever possible.
Internal Validity and Risk of Bias Assessment
The internal validity of each trial included was independently 
evaluated by two authors (A.P., A.M.D.) for bias according 
to The Cochrane Collaboration methods (11) (eMethods 2, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
E416). Eventual divergences were resolved by consensus. We 
rated the potential risk of bias by applying a rating of “low,” 
“high,” or “unclear” to each study.
Data Analysis and Synthesis
For dichotomous variables, we calculated the odds ratio (OR) 
with a 95% CI and in case of common events, defined as the fre-
quency of the event occurring in the control group more than 
or equal to 10%, we calculated the risk ratio (RR) with a 95% 
CI. For continuous outcome, we calculated standardized mean 
difference (sMD) with 95% CI. The p value for the compar-
ison between the groups was calculated, and a p value of less 
than or equal to 0.05 was considered as statistically significant. 
Heterogeneity was assessed using the chi-square test and the 
I2 statistic. We post hoc decided to include only ICU and car-
diac surgery patients, presenting the results separately using 
a random-effects model meta-analysis. Publication bias was 
assessed by visually inspecting funnel plots if 10 or more trials 
are included in the meta-analysis (11). We performed various 
sensitivity, subgroup, and meta-regression analyses (eMethods 
3, Supplemental Digital Content 1, http://links.lww.com/CCM/
E416). Meta-analysis was performed using Review Manager 
(RevMan, Version 5.3. Copenhagen, Denmark: The Nordic 
Cochrane Centre, The Cochrane Collaboration, 2014).
TSA is a methodology that could quantify the statistical re-
liability of data in a cumulative meta-analysis adjusting sig-
nificance levels for the risks of random errors due sparse data 
and repetitive testing on accumulating data. The TSA com-
bines an information size calculation (equal to the cumulated 
sample sizes of all included trials), with a threshold for a sta-
tistically significant effect and a threshold for futility of the 
intervention, both adjusted to better control of type I and type 
II errors. Conclusions made using TSA show the potential to 
be more consistent than those using traditional meta-analysis 
methodology (14–16). Therefore, we performed a post hoc 
random-effects TSA for mortality with the intent of maintain-
ing an overall 5% risk of type I error and a 10% risk of type II 
error, at a power of 90% (14–16). We assumed a relative risk 
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reduction of 15%, and we derived the control event propor-
tion from the actual control dataset. The resulting required 
information size was further diversity (D2)-adjusted. We 
used the TSA software (TSA Viewer [Computer program], 
Version 0.9.5.5 Beta, Copenhagen Trial Unit, Centre for 
Clinical Intervention Research, Rigshospitalet, Copenhagen, 
Denmark, 2016).
RESULTS
The selection process is summarized in Figure 1. A total of 
1,894 studies were identified and, after exclusion of ineligible 
studies, 44 studies (n = 6,455) were included in the meta-anal-
ysis (8–10, 17–61). Major exclusions are reported in eTable 2 
(Supplemental Digital Content 1, http://links.lww.com/CCM/
E416).
Thirty-four studies were single-center, one trial was two-
centers, three trials were three-centers, and one trial was mul-
ticenter. In 10 cases, we received further information from the 
authors (21, 23, 31, 38, 39, 50, 53, 60–62) (eTable 3, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E416).
Three trials were considered to carry a low risk of bias in all 
bias domains (20, 45, 58), five trials were at unclear risk of bias 
(9, 22–24, 40), and 36 trials were at high risk of bias (eFigs. 1 
and 2, Supplemental Digital Content 1, http://links.lww.com/
CCM/E416).
ICU Patients
Sixteen studies (2,857 patients) administered vitamin C sup-
plements in critically ill ICU patients: six in a general ICU 
population (2,425 patients), six in a septic population (260 
patients), three in patients with severe acute pancreatitis (135 
patients), and one in patients with major burns (37 patients) 
(Table 1; and eTable 4, Supplemental Digital Content 1, http://
links.lww.com/CCM/E416).
The administration of vitamin C in critically ill patients 
was associated with no difference in mortality at the longest 
follow-up available (400 of 1,453 patients [28%] in the vi-
tamin C group vs 411 of 1,404 
[29%] in the control group; 
RR, 0.90; 95% CI, 0.74–1.10; 
p = 0.31) (Fig. 2). Funnel plot 
was symmetric, not suggest-
ing publication bias (eFig. 3, 
Supplemental Digital Content 
1, http://links.lww.com/CCM/
E416). Similar results were 
found at subgroup analyses, in 
particular when assessing tri-
als giving only vitamin C, IV/
enteral vitamin C, and high-
dose IV vitamin C (Fig. 3; and 
eTable 5, Supplemental Digital 
Content 1, http://links.lww.
com/CCM/E416).
TSA was inconclusive, since 
19.40% of the information size 
was accrued and the cumu-
lative curve did not reach the 
area of futility (Fig. 4), sug-
gesting the need of further tri-
als for a firm conclusion on the 
effects of vitamin C therapy.
Vitamin C administration 
was associated with no signif-
icant reduction in length of 
ICU stay in critically ill patients 
(eFig. 4, Supplemental Digital 
Content 1, http://links.lww.
com/CCM/E416).
No significant difference in 
AKI between vitamin C and 
control was found (RR, 1.03; 
95% CI, 0.84–1.25; p = 0.78; 
TSA inconclusive) and in Figure 1. Study flow diagram. PRISMA = Preferred Reporting Items Systematic Reviews and Meta-Analysis.
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TABLE 1. Characteristics of the ICU Trials Included in the Analysis
References Journal Country Setting
No. of  
Patients
Experimental  
Intervention Vitamin C Regimen Control
ICU patients
 Bansal  
et al (19)
Saudi J  
Gastroenterol
India Acute  
pancreatitis
39 Vitamin C, vitamin  
E, vitamin A
Vitamin C 1,000 mg  
IV qd for 14 d
No treatment
 Berger  
et al (20)
Crit Care Switzerland Mixed ICU 200 Vitamin C, vitamin 
B1, selenium,  
zinc
Vitamin C 1,100 mg IV 
bid on first 2 d and  
qd until day 5
Placebo
 Crimi  
et al (24)
Anesth Analg Italy Mixed ICU 216 Vitamin C,  
vitamin E






J Surg Res Spain Sepsis/septic 
shock
20 Vitamin C Vitamin C 450 mg IV qd 
for 6 d
Placebo
 Fowler  
et al (7)




24 Vitamin C Vitamin C 12.5 or 
50 mg/kg IV qid for 
4 d
Placebo
 Galley  
et al (31)






30 Vitamin C,  
vitamin E, NAC
Vitamin C 1,000 mg IV 
qd for 1 d
Placebo
 Heyland  
et al (58)




Mixed ICU 1,218 Vitamin C, 
vitamin E, zinc, 
beta-carotene, 
selenium, ±  
glutamine
Vitamin C 1,500 mg  
E qd for 28 d or  
until ICU discharge
Placebo
 Howe  
et al (9)
Am J Crit Care United  
States
Mixed ICU 72 Vitamin C,  
vitamin E, ±  
NAC
Vitamin C 1,000 mg  
E qd for 28 d or  
until ICU discharge
Placebo
 Nabil Habib  
et al (54)




100 Vitamin C Vitamin C 1,500 mg IV 
qid until ICU discharge
No treatment
 Nathens  
et al (8)
Ann Surg United 
States
Mixed ICU 595 Vitamin C,  
vitamin E
Vitamin C 1,000 mg IV 
three times a day until 
ICU discharge
No treatment
 Palli et al  
(33)
Crit Care Greece Mixed ICU 124 Vitamin C, NAC Vitamin C 2,000 mg IV 
2 hr before and at 
10 hr and 18 hr  
following the infusion 
of contrast agent
Placebo




India Acute  
pancreatitis
53 Vitamin C, NAC, 
multivitaminic 
compound
Vitamin C 500 mg  
E qd for 5 d
No treatment
 Schneider  
et al (55)
Clin Nutr Germany Sepsis/septic 
shock





Vitamin C 1,500 mg  
E qd
Placebo






43 Vitamin C, NAC,  
selenium
Vitamin C 2,000 mg  
IV over 24 hr for the 
first 2 d and 1,000 mg 
IV over 24 hr for the 
following 5 d
Placebo
 Tanaka  
et al (47)
Arch Surg Japan Burn patients 37 Vitamin C Vitamin C 66 mg/kg/ 
hr IV for 24 hr
No treatment
 Zabet et al 
(49)




28 Vitamin C Vitamin C 25 mg/kg 
enteral qid for 3 d
Placebo
E = enteral, NAC = N-acetylcysteine, qd = once a day, qid = four times a day.
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other secondary outcomes (eFig. 5 and eTable 4, Supplemental 
Digital Content 1, http://links.lww.com/CCM/E416).
Cardiac Surgery
Twenty-eight trials administered vitamin C supplements in 
cardiac surgery (3,598 patients): 21 in coronary artery by-
pass grafting surgery (2,465 patients) and seven in a mixed 
cardiac surgery population (1,133 patients) (eTables 6 and 
7, Supplemental Digital Content 1, http://links.lww.com/
CCM/E416).
Mortality rate was low and similar between vitamin C 
and control group (15 of 968 patients [1.55%] in the vi-
tamin C group vs 17 of 927 [1.83%] in the control group; 
RR, 1.00; 95% CI, 0.48–2.08; p = 1.00; TSA inconclusive) 
(eFig. 6, Supplemental Digital Content 1, http://links.lww.
com/CCM/E416).
Vitamin C was associated with lower supraventricular 
arrhythmias versus control in cardiac surgery patients (RR, 
0.64; 95% CI, 0.52–0.78; p < 0.0001). Atrial fibrillation 
was the main reported supraventricular arrhythmia. The 
analysis was limited by the high statistical heterogeneity 
(I2 = 57%; p
heterogeneity
 = 0.0005) and significant asymmetry 
of funnel plot, suggesting publication bias; most of the het-
erogeneity was explained by Europe/United States trials, 
which found no difference in postoperative supraventric-
ular arrhythmias (RR, 0.92; 95% CI, 0.76–1.11; p = 0.38) 
in comparison to an important significant effect in other 
countries (RR, 0.49; 95% CI, 0.39–0.61; p < 0.00001) 
Figure 2. Mortality in ICU patients. Forest plot for mortality at longest follow-up available in patients randomized to vitamin C (any regimen) or control. 
df = degrees of freedom, M-H = Mantel-Haenszel.
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(p
subgroup
 < 0.0001) (eFigs. 7 and 8, Supplemental Digital 
Content 1, http://links.lww.com/CCM/E416).
Vitamin C administration was associated to a small re-
duction in postoperative length of ICU stay (sMD, –0.28 d; 
95% CI, –0.43 to –0.13 d; p = 0.0003) and hospital stay (sMD, 
–0.30 d; 95% CI, –0.49 to –0.10 d; p = 0.002). The results were 
limited by high statistical heterogeneity (I2 > 62%; p
heterogeneity
 
< 0.001) and possible publication bias. Subgroup analysis in-
cluding only Europe/United States trials found no effects of 
vitamin C on length of ICU or hospital stay (eFigs. 9-11 and 
eTable 8, Supplemental Digital Content 1, http://links.lww.
com/CCM/E416).
No significant differences in ventricular arrhythmia (OR, 
0.79; 95% CI, 0.33–1.88; p = 0.59; TSA inconclusive), AKI 
(RR, 1.18; 95% CI, 0.74–1.89; p = 0.48; TSA inconclusive), 
and stroke (OR, 0.47; 95% CI, 0.13–1.69; p = 0.25; TSA incon-
clusive) were found (eFig. 6, Supplemental Digital Content 1, 
http://links.lww.com/CCM/E416).
Vitamin C Regimens
The results were consistent at subgroup, sensitivity, and meta-
regression analyses. No effects of dose, length of therapy, route 
of administration, and combination with other antioxidants 
were suggested on any outcome assessed in ICU patients. In 
cardiac surgery, meta-regression suggested possible benefi-
cial effects of longer supplementation with low-dose vitamin 
C on supraventricular arrhythmia (eTables 5, 8 and 9, and 
eMethods 1, Supplemental Digital Content 1, http://links.lww.
com/CCM/E416).
DISCUSSION
This meta-analysis of RCTs showed that vitamin C supplemen-
tation, alone or in association with other antioxidant drugs, 
is associated with no effects on survival and ICU or hospital 
stay in a mixed population of ICU patients. In cardiac surgery, 
the observed beneficial effects on postoperative atrial fibrilla-
tion and ICU/hospital length of stay remain unclear, due to the 
presence of publication bias and subgroup effects according to 
geographical area. The quality and quantity of randomized ev-
idence is still insufficient to draw firm conclusions on clinical 
effects of vitamin C, not supporting neither discouraging the 
systematic administration in critically ill patients.
Cardiac surgery and ICU patients represent two differ-
ent populations, often managed by same medical teams. 
Oxidative stress plays a central role in the pathophysiology of 
Figure 3. Trial sequential analysis for mortality at longest follow-up available in a mixed ICU population. Trial sequential analysis of the included trials 
(black square fill icons) shows that the cumulative Z curve did not cross nor the traditional boundary nor the trial sequential monitoring boundary for 
futility and did not reach the required information size (n = 14,725), suggesting the need for more trials to establish firm conclusions about vitamin C 
effects in critically ill patients. X-axis: the number of patients randomized; y-axis: the cumulative z score; horizontal dotted lines: conventional boundaries 
(upper for benefit, z score = 1.96, lower for harm, z score = –1.96, two-sided, p = 0.05); oblique lines with diamond icons: trial sequential monitoring 
boundaries; oblique line with square fill icons: Z curve; and vertical line with diamonds: required information size.
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inflammatory syndrome in both populations. A high propor-
tion of surgical ICU patients suffer from vitamin C deficiency 
(60) and, in addition, the intense inflammatory response can 
increase metabolic turnover of vitamin C resulting in a severe 
deficiency (61). Analogously, the use of cardiopulmonary by-
pass in cardiac surgery can also induce oxidative stress leading 
to vitamin C depletion (62). An imbalance in the production 
of oxidizing species, such as reactive oxygen species, superoxide 
anions, and other radicals, leads to an increased oxidative stress, 
which causes an increased endothelial permeability with an im-
pairment of microcirculatory flow, an inadequate cell-mediated 
immunity, followed by an activation of apoptotic mitochondrial 
mechanisms that may contribute to cell death and organ failure 
(4, 5). Hypothetically, vitamin C can counterbalance oxidizing 
species, providing a preventing role in the oxidative stress de-
velopment and restoring neutrophil function (4, 5). Some ran-
domized trials included in the present meta-analysis have shown 
an improvement in the inflammatory profile of ICU patients 
Figure 4. Main subgroup analyses in a mixed ICU population. Forest plot for mortality at longest follow-up available in patients randomized to receive: 
only vitamin C, enteral vitamin C (any regimen), IV vitamin C (any regimen), or high-dose IV vitamin C (> 5,000 mg a day). df = degrees of freedom, 
M-H = Mantel-Haenszel.
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receiving vitamin C, confirming its potential immunomodula-
tory activity (7, 8, 24). Indeed, two of these studies showed also 
an improvement in organ dysfunction and failure (7, 8), as also 
suggested by a recent nonrandomized trial (63). Despite vitamin 
C might exert various positive effects, our analysis failed to find 
any benefit in terms of mortality.
Human cells have vitamin C transporters coupled with 
sodium transport and their activity is limited by blood level 
of vitamin C; kidneys excrete the excess of vitamin C and its 
blood levels remain strictly controlled (64). Thus, higher doses 
of vitamin C administered orally (> 400 mg) can saturate the 
intestinal absorption system, achieving plasma concentrations 
that may not be enough to scavenge an excess of oxidizing 
species (64, 65). In this scenario, IV infusion route should be 
the preferred in order to achieve higher plasma concentra-
tions in order to scavenge oxidizing species, protecting from 
their undesirable effects (66). For this purpose, doses higher 
than the usually recommended daily intake could be recom-
mended especially if we consider that, given the hydrophilic 
chemical structure of vitamin C, its plasma concentrations 
may be affected by the higher distribution volume due to 
the positive fluid balance that critically ill patients frequently 
suffer from (67). A dosage of 2–3 g per day might be needed 
to restore normal levels of vitamin C in critically ill patients 
(68). However, our study failed to find any subgroup effects in 
patients randomized to receive IV or high-dose ascorbic acid.
Higher levels of oxidizing species can cause tubular injury 
and glomerular edema, leading to AKI (69). Recent findings 
from a retrospective before-after study suggest that the early 
use of IV vitamin C, together with corticosteroids and thia-
mine, may be effective in preventing progressive organ dys-
function including AKI and reducing the mortality of septic 
shock (63). However, the external validity of this retrospective 
study is limited, mainly due to the nonrandomized, single-cen-
tered design, the small sample size, and the presence of base-
line imbalances and other limitations (70). Our analysis did 
not show any effect in terms of renal failure, even if AKI can 
be a rare complication of vitamin C therapy and represents so 
an outcome of interest, it was underreported in the included 
trials. Results from cardiac surgery, another setting where AKI 
prevention is crucial, were inconclusive too.
In cardiac surgery, vitamin C administration has emerged 
as a strategy of postoperative atrial fibrillation prevention (6). 
The substantial difference in atrial fibrillation results from 
Europe/United States in comparison to other countries, to-
gether with substantial publication bias (6, 71), rise doubts 
on the external validity of the positive aggregate results of our 
meta-analysis on atrial fibrillation in cardiac surgery. Some 
epidemiologic evidence suggested possible larger treatment 
effects in less developed countries (72). Nevertheless, differ-
ences in population characteristics, lifestyle factors including 
nutrition, treatment response, and healthcare systems exist 
and, at least partially, could explain the large difference in 
effect estimate. The prevention of atrial fibrillation, a poten-
tial source of embolic stroke, together with the evidence that 
oxidizing species enhance secondary brain damage by means 
of increased permeability of blood-brain barrier generating 
edema in the acute stage of stroke (73, 74), leave a role for vi-
tamin C. Once again, our results do not firmly support this 
hypothesis.
This is the first comprehensive meta-analysis systematically 
assessing the effects of vitamin C supplementation on impor-
tant clinical outcomes in critically ill patients. With 44 trials 
and more than 6,000 patients, this is the largest meta-analysis 
on this topic performed to date. We focused on some important 
clinical outcomes, such as mortality, and we performed a sys-
tematic review of several databases, aiming to reduce the pos-
sibility of missing minor publications. Traditional limitations 
of aggregate patient data meta-analyses are present, including 
different patients baseline characteristics, clinical subsettings, 
and different vitamin C regimens. In particular, differences 
in routes of administration (enteral vs IV), dosage (low- vs 
high-dose), total duration of supplementation, and combined 
treatment with other antioxidants drugs, increase the incon-
sistency of the aggregate analysis. However, we performed 
several subgroup analyses to explore the possible effects of dif-
ferent vitamin C regimens, with inconclusive results. Most of 
the eligible trials had an high risk of bias and publication bias is 
probable (6). In ICU trials, mortality and length of ICU or hos-
pital stay were the most reported outcomes and several other 
outcomes of interests, such as organ failure or quality-of-life 
endpoints, were modestly and heterogeneously reported. On 
the contrary, atrial fibrillation was the most reported outcome 
in cardiac surgery while mortality was low, making the aggre-
gate analysis underpowered for this latter outcome.
Adverse effects following vitamin C administration are lim-
ited (1, 4) and are mainly related to oxalate kidney stones for-
mation and oxalate nephropathy (10). However, most of the 
included trials did not systematically assess adverse effects, and 
a systematic evaluation before extensive implementation of vi-
tamin C therapy is warranted.
These issues, together with inconclusive results from TSA, 
suggest that the actual randomized evidence on vitamin C sup-
plementation is inconsistent and the current use of vitamin C 
as adjunctive therapy cannot be recommended or discouraged 
neither in a mixed population of ICU patients nor in cardiac 
surgery.
CONCLUSIONS
Vitamin C administration is not associated with a reduction 
in mortality in a mixed ICU population. In cardiac surgery, 
the observed beneficial effects on postoperative atrial fibrilla-
tion and ICU/hospital length of stay remain unclear, due to the 
presence of publication bias and subgroup effects according to 
geographical area. The quality and quantity of evidence is still 
insufficient to draw firm conclusions on the possible effect of 
vitamin C on clinical outcome and aggregate randomized ev-
idence does not support neither discourage the systematic ad-
ministration of vitamin C in ICU or cardiac surgery. Vitamin 
C remains an attractive intervention for future investigations 
aimed at reducing mortality and morbidity.
Copyright © 2019 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
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